Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2).
In this issue
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given